Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants

Heather M. Rozjabeka Janssen Scientific Affairs, LLC, Titusville, NJ, USA;

Craig I. Colemanb School of Pharmacy, University of Connecticut, Storrs, CT, USA;

Veronica Ashtona Janssen Scientific Affairs, LLC, Titusville, NJ, USA;

François Lalibertéc Groupe d’analyse, Ltée, Montréal, QC, Canada;

Paul Oyefesobia Janssen Scientific Affairs, LLC, Titusville, NJ, USA;

Dominique Lejeunec Groupe d’analyse, Ltée, Montréal, QC, Canada;

Guillaume Germainc Groupe d’analyse, Ltée, Montréal, QC, Canada; Correspondence[email protected]

Jeff R. Scheina Janssen Scientific Affairs, LLC, Titusville, NJ, USA;

Zhong Yuand Janssen Research & Development, LLC, Titusville, NJ, USA;

Patrick Lefebvrec Groupe d’analyse, Ltée, Montréal, QC, Canada;

Eric D. Petersone Duke Clinical Research Institute, Durham, NC, USA

Your download is now in progress and you may close this window